Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013

被引:8
|
作者
Subelj, M. [1 ,2 ]
Ucakar, V. [1 ]
Kraigher, A. [1 ]
Klavs, I. [1 ]
机构
[1] Natl Inst Publ Hlth, Ctr Communicable Dis, Ljubljana, Slovenia
[2] European Ctr Dis Prevent & Control ECDC, EPIET, Stockholm, Sweden
关键词
CERVICAL-CANCER VACCINE; ADOLESCENT GIRLS; CONTROLLED-TRIAL; SAFETY; IMMUNIZATION; IMMUNOGENICITY; SURVEILLANCE; AUTOIMMUNE; PROFILE; ADULTS;
D O I
10.2807/1560-7917.ES.2016.21.14.30187
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Adverse events following immunisation (AEFIs) with qHPV reported to the Slovenian AEFI Registry for the first four school years of the vaccination programme were analysed. We calculated annual reporting rates for 11-14 year-old vaccinees with AEFIs, using the number of qHPV doses distributed within the school-based vaccination programme as the denominator. Between September 2009 and August 2013, 211 AEFIs that occurred in 89 vaccinees were reported, a rate of 149.5 vaccinees with AEFI per 100,000 qHPV doses distributed. For five vaccinees, serious AEFIs (8.4 per 100,000 doses distributed) were reported. The highest reporting rates were for fatigue, headache, and fever (>= 38.0 degrees) (53.8, 40.3, and 35.3 per 100,000 qHPV doses distributed, respectively). As no AEFI resulted in permanent sequelae and they all were categorised as serious only due to the criterion of a minimum of one day of hospitalisation, this provides reassurance for the safety of our school-based HPV vaccination programme. Further AEFI surveillance is warranted to provide data for HPV vaccination programme monitoring and evaluation of its safety.
引用
收藏
页码:8 / 13
页数:6
相关论文
共 39 条
  • [1] Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database
    Geier, David A.
    Geier, Mark R.
    IMMUNOLOGIC RESEARCH, 2017, 65 (01) : 46 - 54
  • [2] Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands
    van't Klooster, T. M.
    Kemmeren, J. M.
    van der Maas, N. A. T.
    de Melker, H. E.
    VACCINE, 2011, 29 (28) : 4601 - 4607
  • [3] Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study
    Arnheim-Dahlstrom, Lisen
    Pasternak, Bjorn
    Svanstrom, Henrik
    Sparen, Par
    Hviid, Anders
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
  • [4] A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
    Geier, David A.
    Geier, Mark R.
    CLINICAL RHEUMATOLOGY, 2015, 34 (07) : 1225 - 1231
  • [5] Safety of quadrivalent human papillomavirus vaccine (Gardasil®) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013
    Moro, Pedro L.
    Zheteyeva, Yenlik
    Lewis, Paige
    Shi, Jing
    Yue, Xin
    Museru, Oidda I.
    Broder, Karen
    VACCINE, 2015, 33 (04) : 519 - 522
  • [6] Effect of School-based Human Papillomavirus (HPV) Vaccination on Adolescent Girls' Knowledge and Acceptability of the HPV Vaccine in Ibanda District in Uganda
    Turiho, Andrew Kampikaho
    Okello, Elialilia S.
    Muhwezil, Wilson W.
    Harvey, Steve
    Byakika-Kibwikas, Pauline
    Meya, David
    Katahoire, Anne R.
    AFRICAN JOURNAL OF REPRODUCTIVE HEALTH, 2014, 18 (04): : 45 - 53
  • [7] Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study
    Liu, Erin Y.
    Smith, Leah M.
    Ellis, Anne K.
    Whitaker, Heather
    Law, Barbara
    Kwong, Jeffrey C.
    Farrington, Paddy
    Levesque, Linda E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (21) : E648 - E655
  • [8] Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015
    Arana, Jorge E.
    Harrington, Theresa
    Cano, Maria
    Lewis, Paige
    Mba-Jonas, Adamma
    Li Rongxia
    Stewart, Brock
    Markowitz, Lauri E.
    Shimabukuro, Tom T.
    VACCINE, 2018, 36 (13) : 1781 - 1788
  • [9] Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011
    Naleway, Allison L.
    Crane, Brad
    Smith, Ning
    Daley, Matthew F.
    Donahue, James
    Gee, Julianne
    Greene, Sharon K.
    Harrington, Theresa
    Jackson, Lisa A.
    Klein, Nicola P.
    Tseng, Hung Fu
    Vellozzi, Claudia
    Weintraub, Eric S.
    VACCINE, 2016, 34 (01) : 167 - 171
  • [10] Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community
    Egbon, Michael
    Ojo, Tolulope
    Aliyu, Aminu
    Bagudu, Zainab Shinkafi
    BMC PUBLIC HEALTH, 2022, 22 (01)